The stock of NLS Pharmaceutics Ltd (NLSP) has gone down by -8.47% for the week, with a -54.30% drop in the past month and a -72.78% drop in the past quarter. The volatility ratio for the week is 12.11%, and the volatility levels for the past 30 days are 23.91% for NLSP. The simple moving average for the past 20 days is -38.07% for NLSP’s stock, with a -75.18% simple moving average for the past 200 days.
Is It Worth Investing in NLS Pharmaceutics Ltd (NASDAQ: NLSP) Right Now?
The 36-month beta value for NLSP is at -0.84. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NLSP is 21.84M, and currently, shorts hold a 0.16% of that float. The average trading volume for NLSP on April 04, 2024 was 526.22K shares.
NLSP) stock’s latest price update
The stock price of NLS Pharmaceutics Ltd (NASDAQ: NLSP) has dropped by -9.04 compared to previous close of 0.18. Despite this, the company has seen a fall of -8.47% in its stock price over the last five trading days. InvestorPlace reported 2023-12-04 that NLS Pharmaceutics (NASDAQ: NLSP ) stock is taking a beating on Monday as the company’s shares come down from a rally on Friday. The news that sent shares of NLSP stock higher on Friday concerned an exclusive option to license in-license Aexon Labs’ Dual Orexin Receptor Agonists platform.
NLSP Trading at -56.89% from the 50-Day Moving Average
After a stumble in the market that brought NLSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.00% of loss for the given period.
Volatility was left at 23.91%, however, over the last 30 days, the volatility rate increased by 12.11%, as shares sank -54.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -66.60% lower at present.
During the last 5 trading sessions, NLSP fell by -8.47%, which changed the moving average for the period of 200-days by -83.51% in comparison to the 20-day moving average, which settled at $0.2486. In addition, NLS Pharmaceutics Ltd saw -72.88% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NLSP
The total capital return value is set at 8.84.
Currently, EBITDA for the company is -15.47 million with net debt to EBITDA at 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.58.
Conclusion
In conclusion, NLS Pharmaceutics Ltd (NLSP) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
